Literature DB >> 19399619

African Americans may differ in their reasons for declining hepatitis C therapy compared to non-African Americans.

Marie L Borum, Enaruna Igiehon, Shervin Shafa.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19399619     DOI： 10.1007/s10620-009-0806-4

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  3 in total

1.  Sustained virological response rate to pegylated interferon plus ribavirin for chronic hepatitis C in African Americans: results in treatment-naïve patients in a university liver clinic.

Authors:  Savita Srivastava; Maria Bertagnolli; James H Lewis
Journal:  J Natl Med Assoc       Date:  2005-12       Impact factor: 1.798

2.  Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites.

Authors:  Andrew J Muir; Jeffrey D Bornstein; Paul G Killenberg
Journal:  N Engl J Med       Date:  2004-05-27       Impact factor: 91.245

3.  Reasons why patients infected with chronic hepatitis C virus choose to defer treatment: do they alter their decision with time?

Authors:  Omar S Khokhar; James H Lewis
Journal:  Dig Dis Sci       Date:  2007-03-15       Impact factor: 3.487
  3 in total
  8 in total

1.  Changing trends in complications of chronic hepatitis C.

Authors:  Mei Lu; Jia Li; Loralee B Rupp; Yueren Zhou; Scott D Holmberg; Anne C Moorman; Philip R Spradling; Eyasu H Teshale; Joseph A Boscarino; Yihe G Daida; Mark A Schmidt; Sheri Trudeau; Stuart C Gordon
Journal:  Liver Int       Date:  2017-07-21       Impact factor: 5.828

2.  Race, Age, and Geography Impact Hepatitis C Genotype Distribution in the United States.

Authors:  Stuart C Gordon; Sheri Trudeau; Jia Li; Yueren Zhou; Loralee B Rupp; Scott D Holmberg; Anne C Moorman; Philip R Spradling; Eyasu H Teshale; Joseph A Boscarino; Yihe G Daida; Mark A Schmidt; Mei Lu
Journal:  J Clin Gastroenterol       Date:  2019-01       Impact factor: 3.062

3.  Racial-Ethnic Disparities in Uptake of New Hepatitis C Drugs in Medicare.

Authors:  Jeah Jung; Roger Feldman
Journal:  J Racial Ethn Health Disparities       Date:  2016-12-07

4.  Reasons for HCV non-treatment in underserved African Americans: implications for treatment with new therapeutics.

Authors:  Sarah Schaeffer; Mandana Khalili
Journal:  Ann Hepatol       Date:  2015 Mar-Apr       Impact factor: 2.400

5.  Hepatitis C testing, infection, and linkage to care among racial and ethnic minorities in the United States, 2009-2010.

Authors:  Rania A Tohme; Jian Xing; Youlian Liao; Scott D Holmberg
Journal:  Am J Public Health       Date:  2012-11-15       Impact factor: 9.308

6.  Factors influencing treatment outcome in hepatitis C virus minority patients at an inner-city hospital: A STROBE-complaint article.

Authors:  Zaki A Sherif; Mehdi Nouraie; Rehana Begum; Ali Afsari; Babak Shokrani; Edward Lee; Adeyinka O Laiyemo; Hassan Brim; Hassan Ashktorab
Journal:  Medicine (Baltimore)       Date:  2020-04       Impact factor: 1.817

7.  Racial/Ethnic and Socioeconomic Disparities in Use of Direct-Acting Antivirals Among Medicare Beneficiaries with Chronic Hepatitis C, 2014-2016.

Authors:  Jeah Jung; Ping Du; Roger Feldman; Lan Kong; Thomas Riley
Journal:  J Manag Care Spec Pharm       Date:  2019-11

8.  Estimates of state-level chronic hepatitis C virus infection, stratified by race and sex, United States, 2010.

Authors:  Eric W Hall; Eli S Rosenberg; Patrick S Sullivan
Journal:  BMC Infect Dis       Date:  2018-05-16       Impact factor: 3.090
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.